LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

Discovery of EGFR mutations dramatically changed lung cancer treatment
20th anniversary of landmark findings

When I started fellowship training in the year 2000, the response from everyone when I mentioned my interest in lung cancer was nearly the same: “Are you sure?”

May 31, 2024

Vol.50 No.22

By Suresh S. Ramalingam

In Brief

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

COTA, PreciseDx, and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence-enabled PreciseBreast test that predicts the likelihood of invasive breast cancer recurrence.

May 31, 2024

Vol.50 No.22

In Brief

Personalis, Tempus collaborate to commercialize MRD test

Personalis Inc. announced the commencement of commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease and recurrence in cancer.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.

May 31, 2024

Vol.50 No.22

Clinical Roundup

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Keytruda improves OS for high-risk early-stage TNBC in phase III trial

The phase III KEYNOTE-522 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its overall survival endpoint, in combination with chemotherapy as pre-operative treatment and then continuing as a single agent after surgery for the treatment of patients with high-risk early-stage triple-negative breast cancer.

May 31, 2024

Vol.50 No.22

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

YOU MAY BE INTERESTED IN

Discovery of EGFR mutations dramatically changed lung cancer treatment
20th anniversary of landmark findings

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

Personalis, Tempus collaborate to commercialize MRD test

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Keytruda improves OS for high-risk early-stage TNBC in phase III trial

Renew today!

Subscriber content

Login

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

YOU MAY BE INTERESTED IN

Discovery of EGFR mutations dramatically changed lung cancer treatment20th anniversary of landmark findings

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

Personalis, Tempus collaborate to commercialize MRD test

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

PKMYT1 is a potential target for treatment-resistant ER+ breast cancers

Keytruda improves OS for high-risk early-stage TNBC in phase III trial

Login

Discovery of EGFR mutations dramatically changed lung cancer treatment
20th anniversary of landmark findings